- In March 2025, Novo Nordisk began phase 2 clinical trials on a novel gLp-1 receptor agonist tailored for post-bariatric hypoglycemia, aimed at reducing insulin hypersecretion and stabilizing glucose levels post-meal The development marks a major step forward in offering targeted therapies for PBH patients
- In January 2025, Eli Lilly announced a partnership with the Obesity Society to enhance awareness and early detection of PBH among bariatric patients This initiative is expected to accelerate diagnosis and treatment uptake for PBH, strengthening Lilly’s market presence
- In October 2024, Takeda launched a post-bariatric care initiative in Asia focusing on metabolic complication management, including PBH The campaign includes access to specialized medications and post-op follow-up programs to improve long-term patient outcomes
